[The possibility of S-1 for the treatment of patients with urological cancers].
5-FU is a major anti-tumor agent, and many clinical trials have been conducted to determine the efficacy of 5-FU and fluoropyrimidine derivatives for the treatment of urological cancers. S-1 is an oral fluoropyrimidine derivative that should be tested to demonstrate clinical efficacy for the treatment of urological cancers. Two phase II trials are being conducted to evaluate the efficacy and safety of S-1 as a single agent therapy for patients with hormone-refractory prostate cancer (HRPC) and renal cell carcinoma (RCC).
Akaza
Hideyuki
H
Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan.
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage*; D014571:Urologic Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid